Photo: Teerapat Seedafong/EyeEm/Getty
More than 75 percent of ovarian cancer cases remain undiagnosed until the disease has reached an advanced stage.
A recent clinical trial conducted at nearly 200 sites around the world, including NYU Langone’s Perlmutter Cancer Center, showed that niraparib, a type of drug known as a poly ADP ribose polymerase (PARP) inhibitor, reduced disease progression 57 percent, and the time to disease progression was prolonged 12 months. Bhavana Pothuri, MD, professor in the and a co-investigator of the study, discusses the results on WCBS Newsradio 880.
“The study results move PARP inhibitors for all patients into the front line after platinum-based chemotherapy and really should be considered a new standard of care,” Dr. Pothuri says.
Listen to Dr. Pothuri’s full interview on .
